News & Updates
Filter by Specialty:

Nivolumab plus ipilimumab superior to sunitinib in advanced RCC
First-line treatment with nivolumab plus ipilimumab (NIVO+IPI) results in better survival and response benefits in patients with advanced renal cell carcinoma (aRCC) when compared with sunitinib (SUN), as shown by long-term follow-up data from the CheckMate 214 trial.
Nivolumab plus ipilimumab superior to sunitinib in advanced RCC
01 Mar 2024
Glaucoma tied to increased risk of Alzheimer's, related dementias
Individuals with glaucoma, particular those diagnosed at older ages, are prone to developing Alzheimer’s disease (AD), vascular dementia (VaD), and all-cause dementia (ACD), reports a study.
Glaucoma tied to increased risk of Alzheimer's, related dementias
01 Mar 2024
Interactive multistage robotic positioner developed for intraoperative MRI-guided stereotactic neurosurgery
A joint multidisciplinary team of researchers from the Chinese University of Hong Kong (CUHK), the University of Hong Kong (HKU), University College London, and Johns Hopkins University has developed an interactive, multistage robotic positioner for intraoperative MRI-guided stereotactic neurosurgery aimed at treating patients with neurological diseases, such as brain tumours and Parkinson’s disease.
Interactive multistage robotic positioner developed for intraoperative MRI-guided stereotactic neurosurgery
01 Mar 2024
SBRT on par with HART in limited-stage small-cell lung cancer
Stereotactic body radiotherapy (SBRT) is a safe and effective alternative to hyperfractionated accelerated radiotherapy (HART) in the treatment of limited-stage small-cell lung cancer (LS-SCLC), suggests a recent study.
SBRT on par with HART in limited-stage small-cell lung cancer
29 Feb 2024
Pembrolizumab plus lenvatinib effective against nonclear cell RCC
Pembrolizumab (pembro) plus lenvatinib (lenva) provides durable antitumour activity in patients with advanced nonclear cell renal cell carcinoma (nccRCC) and has a manageable safety profile, according to the results of the phase II KEYNOTE-B61 study.
Pembrolizumab plus lenvatinib effective against nonclear cell RCC
29 Feb 2024
Cilostazol, ticagrelor more cost-effective than standard therapy for acute ischaemic stroke
Use of CYP2C19 genotype-guided antiplatelet therapy with cilostazol or ticagrelor as a substitute to clopidogrel is more cost-effective than conventional antiplatelet therapy for patients with acute minor ischaemic stroke and high-risk transient ischaemic attack, suggests a China study.